Aim Immunotech Inc. · AMEX:AIM
Aim Immunotech — Investor Presentation (February 2023)
29 slides from Aim Immunotech's investor presentation, Feb 6, 2023
Slide 1: AIM ImmunoTech Investor Presentation Q1 2023
NYSE American: AIM aimimmuno.com AIM : ImmunoTech Investor Presentation - Q1.2023
Slide 2: Forward Looking Statements
Forward Looking Statements Some of the statements included in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Among other things, for those statements, we claim the protection of safe harbor for forward-looking statements contained in the Private
Slide 3: Investor Highlights
lavestor Highlights Late-stage clinical immuno-pharma company focused on developing therapeutics across a number of disease areas Our lead program, Ampligen®, is an immuno-modulator that has shown broad spectrum activity in in-vitro and animal testing and is being evaluated in clinical studies of a
Slide 4: Broad Oncology Pipeline Across Multiple Unmet Needs
Broad Oncology Pipeline Across Multiple Unmet Needs Priority Development Programs aon svete _—— Se tl Sass First Patient Expected in Q1 2023 ste sacearerectccancer "re eniceeomm an Sibnodaie / Post-COVID Single Agent FY] Study Launch Expected Q1 2023 Metastatic Pancreatic Ductal Ampligen and Adenoca
Slide 5: Lead Program Ampligen (rintatolimod)
Lead Program Ampligen® (rintatolimod) Induces wide range of immunologic / antitumor activities Qaim
Slide 6: Clinically Demonstrated
Clinically Demonstrated Demonstrated clinical potential eee etoe, .° fe a - . . / encouraging results in multiple Che Disease preclinical models and clinical y Area Focus studies Demonstrated Safety ) ” Generally well tolerated across a Oncology number of clinical studies COVID-19 ME/CFS Long COVID
Slide 7: Oncology Programs
Oncology Programs Immuno-Therapy Targeting Multiple _ Cancers with High-Unmet Need
Slide 8: Ampligen: Mechanism in Oncology
Ampligen®: Mechanism in Oncology Reprogramming of the Tumor Microenvironment to Convert “Cold” Tumors Into “Hot” Tumors that will be Responsive to Checkpoint Blockage Goal is to unleash the cellular immune response to attack and destroy cancer cells and increase survival* Ampligen’ is the only known
Slide 9: Ensuring Effective Chemokine Modulation in Tumors is Important
Ensuring Effective Chemokine Modulation in Tumors is Important for Teff Cell Infiltration and Increased Survival Ampligen® (dsRNA/TLR3 agonist) containing cocktails have shown an ability in vivo Am pl Ige n® to increase CXCL10 and decrease CCL22 intratumorally with associated increase in the Teff/Tr
Slide 10: Pancreatic Cancer Market Opportunities
Pancreatic Cancer Market Opportunities 62,210 New Cases Annually? 49,830 Deaths Annually 1. _ National Cancer = Ovarian Ca tute: Surveillance, Epi gy and End Results, ia
Slide 11: Promising Results From Early Access Program Published in Cancers
Promising Results From Early Access Program (EAP) Published in Cancers Statistically Significant Increased Overall Survival Compared to Historical Controls in Treatment of Late-Stage Pancreatic Cancer Survival Data: Median overall survival (OS) was 19 months in the Ampligen® cohort compared to 12 mo
Slide 12: Ampligen Maintenance Therapy after FOLFIRINOX
Ampligen® Maintenance Therapy after FOLFIRINOX Improves Overall and Progression-Free Survival Progression-free survival Overall survival 100 ewli== Ampligen ewel== Ampligen g =—L— Subset matched controls _ =—L— Subset matched controls x ES Ww a) 6 50 0 te) 0 1D 34 36 0 12 24 36 48 Time in months sin
Slide 13: Long-Term Survivors Exhibit Decreased SII and NLR
Pancreatic Long-Term Survivors Exhibit Decreased SIIl Cancer and NLR as well as Increased B-Cell Counts sill NLR B-Cells we * § seq =r—— 7. ** gs * £ 4 800 s i 4 4000 g . = o £ Fe) | 5 600 & 2 10 ° 7 4 3000 ra S l z E Z ra = xk 5 400 § 2000 2 ‘ee | 2 £ gos 2 £ 6 2 ‘2 1000 ° 8 E 5 2 E Fe 0 13 A. Syst
Slide 14: Pancreatic Cancer Clinical Activity
Pancreatic Cancer Pancreatic Cancer Clinical Activity Investigator i Early Access Phase 2 Locally Advanced Pancreatic y Metastatic Pancreatic Ductal Adenocarcinoma Late-Stage Pancreatic Cancer Initiated Program Adenocarcinoma Program Status Study Launch Expected in Q1 2023 Status Early Access Progra
Slide 15: Additional Target Oncology Indications
Additional Target Oncology Indications Represent Significant Unmet Need 19,880 287,850 | 151,030 99,780 New Cases Annually? New Cases Annually* New Cases Annually* New Cases Annually 12,810 43,250 52,580 7,650 Deaths Annually? Deaths Annually? Deaths Annually Deaths Annually 80% recurrence rate 12-2
Slide 16: Additional Ongoing Oncology Development Programs
Additional Ongoing Oncology Development Programs Advanced, Recurrent . Interim Data Published April 2022 Ovarian Cancer . (NCT02432378) Metastatic Triple Negative Phase 1 Data Published April 2022 Breast Cancer Early-Stage Triple Negative Analyzing Data Breast Cancer eee Colorectal Cancer Phase 2a F
Slide 17: Our AIM: Immune System Disorder
Our AIM Immune System Disorder ME/CFS | Long COVID ==" ae
Slide 18: Ampligen for the Treatment of ME/CFS
Ampligen® for the Treatment of ME/CFS Approved for the treatment of Severe CFS in Argentina Only late-stage program in development in the U.S. for the treatment of ME/CFS Developing protocol for confirmatory Phase 3 trial, required for U.S. NDA
Slide 19: Ampligen as a Potential Treatment of ME/CFS
Ampligen® as a Potential Treatment of ME/CFS Positive Results from Phase 3 Study Demonstrated Significant Improvement in the Primary Endpoint, Exercise Treadmill Tolerance (ETT) 60.0% 50.0% 40.0% 30.0% 20.0% 10.0% 0.0% 39.0% p=0.013! (a=15.9%) 23.1% ITT Population 51.2% p=0.003! (A=33.6%) 17.6% Resp
Slide 20: Ampligen as a Potential Treatment of Post-COVID Conditions
Ampligen® as a Potential Treatment of Post-COVID Conditions Chronic IIIness Following COVID-19 Shares Similar Characteristics to ME/CFS ca COVID-Induced Chronic Fatigue (Post-COVID Conditions or ‘Long Haulers’) Phase 2 Study Status Study Launch Expected Q1 2023 Number of Subjects Up to 80 Fatigue Br
Slide 21: Viral Disease Programs
iral Disease Programs SARS-CoV-2 (COVID-19)
Slide 22: Ampligen as a Potential Treatment of SARS-CoV-2
Ampligen® as a Potential Treatment of SARS-CoV-2 100 Potentially broad-spectrum immune system 90 response against SARS-CoV-2 (COVID-19) 80 _ 70 Uniquely targets TLR3 without activation of 3 60 the inflammatory cytosolic helicases 2 50 = 40 Based upon Ampligen’s mechanism of action, it 3 30 has the p
Slide 23: Ongoing Phase 1/2 Study for Treatment of COVID-19 in Cancer Patients
Ongoing Phase 1/2 Study for Treatment of COVID-19 in Cancer Patients Status Recruiting Number of Subjects Up to 64 Study Drug Ampligen’ and IFN alpha-2b Primary Endpoint Incidence of AEs, Kinetics of Viral Load Study Partner Roswell Park Clinical Trials NCT# NCT04379518
Slide 24: Our AIM Corporate Overview
Slide 25: Intellectual Property Portfolio — Market Exclusivity
Intellectual Property Portfolio — Market Exclusivity 7 year market exclusivity following FDA approval Ampligen® 10 year market exclusivity following EMA approval Orphan Drug Designation (FDA and EMA) 25 Qaim
Slide 26: Financial Snapshot
Financial Snapshot Sufficient Capital to Fund Operations Through End of 2023 and Multiple Key Clinical Milestones e Volume? _ Shares Outstanding? 26 Qa 1: As of September 30, 202252: 2 of $0.77; 3: AS of March 25,2022
Slide 27: Proven Management Team
Proven Management Team 6 ©) EQUELS ROE AEE LAW FIRM fil GreenbergTraurig [usin ATTORNEYS AT LAW F DREXEL UNIVERSITY David R. Strayer, M.D. : Collegeof Hi Hahnemann Chief Scientific & Medical Officer Medicine University HOSPITAL Rodino Consulting; Rodino & Rodino; Rodino & Scalera Inc.; j Foundation
Slide 28: Investment Summary
Investment Summary Advancing Lead Program Ampligen®, for the Potential Treatment of Multiple High-Value Oncology, Viral and Immune-System Disorders Indications Sufficient Capital to Fund Operations Through Multiple Key Clinical Milestones 28 Qaim
Slide 29: aimimmuno.com
NYSE American: AIM aimimmuno.com AIM : ImmunoTech
AIM ImmunoTech — Investor Presentation (February 2023) on 6ix